DocGo (DCGO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Election of two Class II directors: Vina Leite and James M. Travers, with board recommendation to vote for both.
Advisory vote to approve named executive officer compensation, recommended for approval.
Proposal to approve a reverse stock split at a ratio between 1-for-5 and 1-for-10, with a proportionate reduction in authorized shares, at the board's discretion.
Amendment to the certificate of incorporation regarding waiver of corporate opportunities, recommended for approval.
Amendment to limit liability of certain officers as permitted by Delaware law, recommended for approval.
Ratification of Urish Popeck & Co., LLC as independent auditor for the year ending December 31, 2026.
Board of directors and corporate governance
Board recommends all proposals, including director elections and amendments, for shareholder approval.
Board retains discretion on timing and ratio of the proposed reverse stock split.
Executive compensation and say-on-pay
Advisory vote on executive compensation for named executive officers is included as a key agenda item.
Latest events from DocGo
- Record growth, board transition, and tech-driven initiatives mark a pivotal year.DCGO
AGM 2026 - Transitioning to proactive, tech-enabled care, the company targets growth and profitability.DCGO
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Tech-driven healthcare platform posts strong growth, raises guidance, and targets profitability.DCGO
21st Annual Needham Technology, Media, & Consumer Conference - Rapidly scaling mobile healthcare and transport with strong growth, tech integration, and expanding margins.DCGO
Investor presentation - Q1 revenue was $75.6M, net loss widened, but 2026 guidance was raised on strong core growth.DCGO
Q1 2026 - Proxy seeks approval for director elections, reverse stock split, and key governance amendments.DCGO
Proxy filing - Key proposals include director elections, a reverse stock split, and governance amendments.DCGO
Proxy filing - Q3 revenue dropped 26%, but net income and adjusted EBITDA rose, with guidance raised.DCGO
Q3 2024 - Q2 revenue up 31% to $164.9M, net income and margins rose, cash flow guidance increased.DCGO
Q2 2024